Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting

NEXT STORY
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
PREV STORY
Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results

author_avatar
NASDAQ Market News

Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer

NEW BRUNSWICK, N.J., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American:HEB) said, ...

author_avatar
NASDAQ Market News

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

author_avatar
NASDAQ Market News